Quantum Biopharma (QNTM) Short term Debt (2019)

Quantum Biopharma's (QNTM) quarterly Short term Debt came in at $2.0 million in Q4 2019.

Quantum Biopharma (QNTM) Short term Debt (2019) Analysis & Trends

Quantum Biopharma has disclosed Short term Debt across 1 years of filings, most recently posting $2.0 million for Q4 2019.

Short term Debt for Q4 2019 came in at $2.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $2.0 million (changed N/A YoY), and the FY2019 annual result was $2.0 million, changed N/A from the prior year.
Short term Debt came in at $2.0 million for Q4 2019 at Quantum Biopharma.
In the past five years, Short term Debt ranged from a high of $2.0 million in Q4 2019 to a low of $2.0 million in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn

Historic Data

Download Data

Date	Value
Dec 31, 2019	2.00 Mn